BioCentury | Jan 14, 2021
Finance

With €127M series B, cancer vaccine developer IO Biotech raises second-largest European venture round in the past year

...By Danielle Golovin, Staff Writer IO Biotech parlayed early clinical data into a €127 million ($154.8 million...
...months, behind the €560 million round CureVac N.V. (NASDAQ:CVAC) closed in July ahead of its August IPO. IO Biotech ApS...
...ONO-4538 (Compound #), MDX-1106 (Compound #), BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) IO102 IO103 Keytruda, pembrolizumab (MK-3475, lambrolizumab) IO Biotech ApS HBM...
BioCentury | Sep 3, 2019
Company News

Management tracks: Tempus brings on former FDA chief of staff; plus Bayer, Genfit, Accent and more

...Pharma Ltd. (Windsor, U.K.) named Soren Bregenholt as CEO. He was most recently CBO at IO Biotech ApS...
BioCentury | Apr 20, 2018
Product Development

Lessons from the ECHO chamber

...the immune system is not activated. Therefore, taking the brakes off won’t work,” Krieg said. IO Biotech ApS...
...“flag” to bring effector T cells into the tumor microenvironment, CEO Mai-Britt Zocca told BioCentury. IO Biotech...
...Phase I data demonstrating IO102’s efficacy as monotherapy to treat non-small cell lung cancer (NSCLC). IO biotech...
BioCentury | Oct 13, 2017
Company News

Management tracks: Verastem, OxThera

...director and global development leader for the calcimimetic franchise at Amgen Inc. (NASDAQ:AMGN). Immuno-oncology company IO Biotech ApS...
BioCentury | Feb 1, 2016
Finance

Emerging in Denmark

...dedicated pool of money. It led a €11 million ($12 million) series A round for IO Biotech ApS...
...NASDAQ:GILD), Foster City, Calif. H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Insusense Therapeutics ApS, Copenhagen, Denmark IO Biotech ApS...
BioCentury | Jan 11, 2016
Financial News

IO Biotech completes venture financing

IO Biotech ApS , Copenhagen, Denmark Business: Cancer Date completed: 2016-01-05 Type: Venture financing Raised: EUR11 million ($12 million) Investors: Lundbeckfond Emerge; Novo A/S WIR Staff cancer...
BioCentury | Jan 6, 2016
Financial News

IO Biotech raises EUR 11M in series A

...Immuno-oncology play IO Biotech ApS (Copenhagen, Denmark) raised EUR 11 million ($12 million) in a series A round...
...investor Novo A/S (Hellerup, Denmark). Lundbeckfond Emerge is the early stage investment unit of Lundbeckfonden. IO Biotech...
...2,3-dioxygenase (INDO; IDO) and to start a clinical study of a vaccine targeting PD-L1 . IO Biotech...
BioCentury | Jan 19, 2015
Financial News

IO Biotech completes venture financing

IO Biotech ApS , Copenhagen, Denmark Business: Cancer Date completed: 2015-01-12 Type: Venture financing Raised: EUR3 million ($3.5 million) Investor: Novo Seeds WIR Staff cancer...
Items per page:
1 - 8 of 8
BioCentury | Jan 14, 2021
Finance

With €127M series B, cancer vaccine developer IO Biotech raises second-largest European venture round in the past year

...By Danielle Golovin, Staff Writer IO Biotech parlayed early clinical data into a €127 million ($154.8 million...
...months, behind the €560 million round CureVac N.V. (NASDAQ:CVAC) closed in July ahead of its August IPO. IO Biotech ApS...
...ONO-4538 (Compound #), MDX-1106 (Compound #), BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) IO102 IO103 Keytruda, pembrolizumab (MK-3475, lambrolizumab) IO Biotech ApS HBM...
BioCentury | Sep 3, 2019
Company News

Management tracks: Tempus brings on former FDA chief of staff; plus Bayer, Genfit, Accent and more

...Pharma Ltd. (Windsor, U.K.) named Soren Bregenholt as CEO. He was most recently CBO at IO Biotech ApS...
BioCentury | Apr 20, 2018
Product Development

Lessons from the ECHO chamber

...the immune system is not activated. Therefore, taking the brakes off won’t work,” Krieg said. IO Biotech ApS...
...“flag” to bring effector T cells into the tumor microenvironment, CEO Mai-Britt Zocca told BioCentury. IO Biotech...
...Phase I data demonstrating IO102’s efficacy as monotherapy to treat non-small cell lung cancer (NSCLC). IO biotech...
BioCentury | Oct 13, 2017
Company News

Management tracks: Verastem, OxThera

...director and global development leader for the calcimimetic franchise at Amgen Inc. (NASDAQ:AMGN). Immuno-oncology company IO Biotech ApS...
BioCentury | Feb 1, 2016
Finance

Emerging in Denmark

...dedicated pool of money. It led a €11 million ($12 million) series A round for IO Biotech ApS...
...NASDAQ:GILD), Foster City, Calif. H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Insusense Therapeutics ApS, Copenhagen, Denmark IO Biotech ApS...
BioCentury | Jan 11, 2016
Financial News

IO Biotech completes venture financing

IO Biotech ApS , Copenhagen, Denmark Business: Cancer Date completed: 2016-01-05 Type: Venture financing Raised: EUR11 million ($12 million) Investors: Lundbeckfond Emerge; Novo A/S WIR Staff cancer...
BioCentury | Jan 6, 2016
Financial News

IO Biotech raises EUR 11M in series A

...Immuno-oncology play IO Biotech ApS (Copenhagen, Denmark) raised EUR 11 million ($12 million) in a series A round...
...investor Novo A/S (Hellerup, Denmark). Lundbeckfond Emerge is the early stage investment unit of Lundbeckfonden. IO Biotech...
...2,3-dioxygenase (INDO; IDO) and to start a clinical study of a vaccine targeting PD-L1 . IO Biotech...
BioCentury | Jan 19, 2015
Financial News

IO Biotech completes venture financing

IO Biotech ApS , Copenhagen, Denmark Business: Cancer Date completed: 2015-01-12 Type: Venture financing Raised: EUR3 million ($3.5 million) Investor: Novo Seeds WIR Staff cancer...
Items per page:
1 - 8 of 8